William J. Catalona, M.D. – Medical Director of the Urological Research Foundation
CURRICULUM VITAE
| Marital Status: | Married: Janet Flenner Catalona One Child: Alexander Paul Catalona | ||
| Contact Information: | 675 North St. Clair Street, Suite 20-150 Chicago, IL 60611 Phone: 312 695-4471 Fax: 312 695-7030 E-Mail: wcatalona@nm.org | ||
| Pre-Medical Education: | Otterbein College, Westerville, OH 1964 – B.S. | ||
| Medical Education: | Yale Medical School, New Haven, CT 1968 – M.D. | ||
| Graduate Hospital Clinical Experience:
| 1968-1969 – Intern (Surgery), Yale-New Haven Hospital 1969-1970 – Resident (Surgery), University of California, San Francisco, California 1970-1972 – Clinical Associate, NIH/NCI, National Cancer Institute, Bethesda, Maryland 1972-1976 – Resident (Urology), Johns Hopkins Hospital, Baltimore, Maryland | ||
| Academic Positions: | 1976-1982 – Associate Professor of Surgery (Urology), Washington University School of Medicine 1982-2003 – Professor of Surgery (Urology), Washington University School of Medicine 1984-1998 – Chief of Urologic Surgery, Washington University School of Medicine 2003-present – Professor of Urology, Northwestern University Feinberg School of Medicine 2003-present – Director of the Clinical Prostate Cancer Program, Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine | ||
| Hospital Appointments: | Barnes-Jewish Hospital St. Louis Children’s Hospital Barnes-Jewish West County Hospital Northwestern Memorial Hospital | ||
| Licensure: | Virginia | 21472 | (1971) |
| Maryland | D13338 | (1971) | |
| California | G26426 | (1974), G192274 (2015) | |
| Missouri | R7016 | (1976) | |
| Illinois | 036108209 | 036108209 (2003) | |
| Certification: | American Board of Urology, 1978 | ||
| Military Service: | US Public Health Service, National Cancer Institute Surgery Branch, NIH, Bethesda, Maryland (1970-72) | ||
| Societies: | Fellow, American College of Surgeons American Urologic Association North Central Section, American Urologic Association American Association of Genitourinary Surgeons Clinical Society of Genitourinary Surgeons, President (2011) Society of Urologic Oncology, President (1995-96) | ||
| Awards and Honors: James Ewing Society Award for Cancer Research, 1972 Mid-Atlantic Section AUA, Resident Clinical Research Award, 1974 Clinical Research Award, AUA Grayson Carroll Essay Contest, 1974 American Cancer Society Clinical Fellow, 1974 – 1975 American Cancer Society Junior Faculty Fellow, 1977 – 1979 C.E. Alken Award for Research in Urology, 1979 American Urological Association, Gold Cystoscope Award, 1986 American Urological Association Annual Audio-Visual Award, First Prize, 1988 American Urological Association, Hugh Hampton Young Award, 1994 The Johns Hopkins Society of Scholars, 1994 American Urological Association, Eugene Fuller Triennial Prostate Medal, 1998 American Association of Genitourinary Surgeons, Barringer Medal, 1999 Fellow, St. Louis Academy of Science, 2002 American Association of Genitourinary Surgeons, Edward L Keyes Medal, 2003 Florida Prostate Cancer Network, Gen. H. Norman Schwartzkopf Pioneer in Prostate Cancer Award, 2005 Society of Urologic Oncology, Charles Huggins Award, 2005 Prostate Cancer Foundation, D.S. Coffey Physician-Scientist Award, 2005 National Prostate Cancer Coalition’s Golden Glove Award, 2006 New York Academy of Medicine, Ferdinand C. Valentine Medal, 2007 Alpha Omega Alpha, Honorary Medical Society, Northwestern Univ. 2010 Ramon Guiterrez Lecturer, American Urological Association 2011 Society of Basic Urology Research Distinguished Service Award 2013 German Urological Association – Honorary Member 2013 William Wallace Scott Lecturer, Johns Hopkins, 2014 Northwestern University Urology Chief Residents award for “outstanding contributions to resident education” (2015) Clinical Society of Genitourinary Surgeons Honorary Member (2016) Castle-Connolly National Physician of the Year Award (2016) American Urological Association, Honorary Member (2017) Urology Care Foundation Richard D. Williams, MD Prostate Cancer Research Excellence Award (2019) American Urological Association, Ramon Guiteras Award (2020) | |||
| Special Committee Appointments: Assistant Editor, Journal of Urology, 1978-1986 Editorial Board, Investigative Urology, 1980-1985 Field-Editor, World Journal of Urology Editor, Quest 1996 – present American Board of Urology Certification Examination Committee 1982-1986 (leader of urologic oncology section 1986) Editorial Board, Advances in Urology Member Consultant, American Urological Association Program Committee Editorial Board, Urological Survey Section, Journal of Urology, 1988-1992 Consultant, NIH Organ Systems Coordinating Center Prostate Cancer Working Group Scientific Advisory Committee, National Kidney Foundation Medical Affairs Committee, American Cancer Society Consulting Editor, Urology Medical Advisory Committee, CaP CURE (Prostate Cancer Foundation) Spokesperson on Prostate Cancer Screening, American Urological Association, Inc. Medical Director, Urological Research Foundation 1984 –present President, Society of Urologic Oncology (1995-1996) Member National Comprehensive Cancer Network Panel on Early Detection of Prostate Cancer Co-Chair, Genetics Working Group, Prostate Specialized Programs of Research Excellence (SPORE), National Cancer Institute, NIH/NCI PI SPORE in Prostate Cancer – 2013-present | |||
| Research Activities: | Cancer Biology (Intravesical BCG Therapy for Bladder Cancer, PSA-based Screening for Prostate Cancer, Genetics of Prostate Cancer) | ||
Grant Support:
National Institutes of Health
1977-80 Principal Investigator – Immunologic Characterization of Copenhagen
Rat Prostatic Adenocarcinoma
1978-81 Principal Investigator – Suppressor Cells in Bladder Cancer Patients
1980-83 Co-Investigator – Interferon: Effect on Immunity to Bladder Tumors
1984-92 Co-Investigator – Mechanisms of Surgical Adjuvant Intravesical BCG
1986-89 Co-Investigator – Surgery and BCG in Bladder Cancer: Immunologic Effects
1992-93 Co-Investigator – Intravesical BCG for Bladder Cancer: Role of Fibronectin
1992-96 Principal Investigator – Special Project on Research Excellence – Prostate Cancer
1993-97 Co-Investigator – Intravesical BCG for Bladder Cancer: role of Fibronectin
Biogen Company
1985-89 Principal Investigator – Comparison of Immuneron With Depo Provera In Patients With
Metastatic Renal Cell Carcinoma
Adria Laboratories
1989-91 Principal Investigator – Combination Doxorubicin and BCG In The Treatment of Bladder
Cancer
American Cancer Society
1992-93 Principal Investigator – American Cancer Society Clinical Oncology Fellowship Award
1993-94 Principal Investigator – American Cancer Society Clinical Oncology Fellowship Award
1994-95 Principal Investigator – American Cancer Society Clinical Oncology Fellowship Award
United States Army Medical Research and Material Command
1999-02 Co-Investigator – An LOH Study of Chromosome 8 in Multiplex Prostate Cancer Sibships
Hybritech Incorporated
1989-present Principal Investigator – Prostate Specific Antigen Screening For Prostate Cancer
CaPCURE
1994-present Principal Investigator – Establishment of Prostate Cancer Tissue Bank
Harvard/NIH Subcontract
1997-98 – Prinicipal Investigator – Dietary and Biochemical Markers of Prostate Cancer Risk
USAMRMC
1998-2000 – Principal Investigator – Patient Preferences for Outcomes Associated with Surgical
Management of Prostate Cancer
Boehinger Mannheim Corp.
1998 – Principal Investigator – Determination of Elecsys Total and Free PSA Levels
Monsanto
1998-1999 Principal Investigator – Cyclooygenase Inhibitors in Prostate Cancer: Phase I
UroMed
1998-2000 A Multi-Center Clinical Evaluation of the CaverMap Surgical Aid for us During Radical
Prostatectomy
Pfizer, Inc.
1998 Principal Investigator – A Study to Evaluate the Impact of Viagra on Treatment Satisfaction
CONTRIBUTIONS TO SCIENCE
1. Prostate-specific antigen (PSA) as a first-line screening test for PCa
Historical background: Before the work of my colleagues and me, the digital rectal examination was the only first-line screening test for PCa. PSA had been used for monitoring the response to treatment of patients already diagnosed with PCa, but it was not believed that it could be used as a first-line screening test.
Central findings: In a prospective study of >1600 patients, we demonstrated that PSA outperformed DRE as a first-line screening test for PCa.a
Influence of the findings on the progress of science: This ushered in the global PSA screening era, was a precursor of the pivotal study that led to FDA approval of PSA as an aid to the early detectionb, and served as an impetus for the randomized clinical trials of PSA-based screening. Two of these trials demonstrated a stage migration and 21-44% decrease in PCa-specific mortality. c, d Ecological data from the U.S. and Canada also show a > 50% decrease in PCa mortality during the PSA screening era. The PSA Study database also was a resource for numerous studies defining the operating characteristics of PSA testing.
Application of findings to health or technology: Despite the controversy concerning PSA screening, most major professional organizations currently recommend a shared decision making process concerning PSA testing.
My specific role: I conceived, executed and authored the original PSA study and led the multi-institutional pivotal study that achieved FDA approval of the PSA test. Manuscripts a and b below, on which I was first author, have been cited over 2350 times in papers by authors from 69 countries written in 22 different languages, and have been cited over 90 times in patents (Scopus).
a. Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324:1156-61
b. Catalona WJ, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol.1994; 151:1283-90.
c. Schröder FH, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl JMed. 2012; 366:981-90.
d. Hugosson J, et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 2010:725-32. PMCID: PMC4089887
2. Free-to-total PSA test to increase the specificity of PSA screening
The total PSA test has limited specificity and can lead to false positive results upon testing. The free/total PSA ratio improves specificity of PCa screening in men with elevated total serum PSA levels and can reduce unnecessary prostate biopsiesa,b This work led to the pivotal study that achieved FDA approval of the free PSA test to improve the accuracy of PSA testing.c The free PSA test is now widely used in PSA-based screening for PCa. I helped conceive, execute and write the original free PSA study and led the multi-institutional pivotal study that achieved FDA approval of the free PSA test. As a group, the papers below have been cited over 1780 times in scholarly works and 46 times in patents (Scopus).
a. Catalona WJ, et al, Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274:1214-20.
b. Catalona WJ, et al. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277:1452-5.
c. Catalona WJ, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279:1542-7.
3. Pro PSA test to increase the specificity of PSA screening for clinically significant PCa
Adding pro-PSA measurements further improves specificity of PCa screening in men with elevated total serum PSA levels over free PSA and complexed PSA tests. My work has demonstrated that pro-PSA significantly improves cancer detection, further reduces unnecessary biopsies, and preferentially detects aggressive prostate cancers.a,b,d This work led to the pivotal study that achieved FDA approval of the [-2] pro PSA as part of the Prostate Health Index (phi) to improve the accuracy of PSA testing.c The phi test is commercially available and is increasingly gaining use for PCa screening. I helped conceive, execute and author the original pro-PSA studies and led the multi-institutional pivotal study that achieved FDA approval of the Prostate Health Index (phi) test. The manuscripts listed below have been cited collectively in scholarly works over 350 times by authors representing 32 countries and written in 11 languages. 3d has also received media coverage, including a feature in Reuters news (Scopus and Altmetric).
a. Catalona WJ, et al. Serum pro-prostate specific antigen improves cancer detection compared to free and complexed PSA in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003; 170:2181-5.
b. Catalona WJ, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004; 171:2239-44.
c. Catalona WJ, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185:1650-5. PMCID: PMC3140702
d. Loeb S, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015; 193:1163-9. PMCID: PMC4404198
4. Discovery and replication of SNPs associated with PCa susceptibility
There was limited knowledge of single nucleotide polymorphisms (SNPs) associated with PCa susceptibility. I collaborated in the study by deCODE Genetics that discovered the first PCa risk allele on chromosome 8q24 and subsequently more than 10 other PCa risk SNPs. This was the first of many genome-wide association studies that have identified ~160 common PCa risk SNPs. These studies have increased the knowledge of genetic factors associated with PCa susceptibility. During these studies, we created a well-annotated biorepository for future studies. I provided DNA samples and phenotype data for the replication phase of the studies and participated in the writing of the manuscripts. Collectively, the manuscripts below have been cited over 1083 times in works by authors in 69 countries, including over 40 books and book chapters. These papers have also been cited 90 times in patents. (Scopus)
a. Amundadottir LT, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006; 38:652-8.
b. Gudmundsson J, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet. 2012; 44:1326-9. PMCID: PMC3562711
c. Gudmundsson J, Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007; 39:977-83.
d. Gudmundsson J, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med. 2010; 2:62ra92. doi:10.1126/scitranslmed.3001513. PMCID: PMC3564581
5. Discovery and replication of SNPs associated with PCa susceptibility/aggressiveness
There is limited knowledge of SNPs associated with PCa aggressiveness. I participated in the early microsatellite studies focusing on PCa aggressivenessa as well as linkage studies, association studies and whole-exome sequencing studies of the ICPCG studies in familial PCa casesb, and in the SPORE Genetics Working Group studies of aggressive PCa risk alleles.c,d These studies have increased the knowledge of genetic factors associated with the more aggressive PCa phenotypes. This work led to the identification of genetic variants associated with PCa aggressiveness and have pointed the way to future studies that may have practical applications for targeted screening and active surveillance versus immediate treatment. I provided DNA samples and phenotype data for the discovery and replication phases of the studies and participated in the design, organization, execution, analysis and writing of the SPORE Genetic Working Group studies. This newer work has been cited a total of 127 times by authors in 32 countries (Scopus).
a. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ. Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet. 2000 67:92-9. PMCID: PMC1287106
b. Teerlink CC, et al. International Consortium for Prostate Cancer Genetics. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet. 2014; 133:347-56. PMCID: PMC3945961
c. Catalona WJ, et al. National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res. 2011; 71:3442-6. PMCID: PMC3096727
d. Helfand BT, Roehl KA, Cooper PR, Catalona WJ. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet. 2015; 134:439-50.
Download Dr. Catalona’s full CV here.
